Filing Flows › Companies › Prestige Consumer Healthcare › Timeline
Prestige Consumer Healthcare stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−29.9% to $42.98
Prestige Consumer Healthcare (PBH) stock fell 30% over the last 252 sessions, to $42.98. On the way it reported 5 quarters, its insiders filed 3 open-market trades, and the company filed 6 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 5, 2026 | Earnings | Earnings: beat the EPS estimate by 5.3% | −18.4% (−13.9% vs SPY) | — | — |
| Aug 14, 2026 | 8-K | Directors and officers: departures, appointments, pay | −2.6% (−2.2% vs SPY) | −0.1% (+1.2% vs SPY) | −9.6% (−7.1% vs SPY) |
| Aug 6, 2026 | Earnings | Earnings: beat the EPS estimate by 12.0% | +2.7% (+2.9% vs SPY) | −1.3% (−1.7% vs SPY) | −0.8% (−1.2% vs SPY) |
| Jul 15, 2026 | 8-K | Material definitive agreement | +4.5% (+5.1% vs SPY) | +1.4% (+2.3% vs SPY) | +6.0% (+2.9% vs SPY) |
| Jul 6, 2026 | 8-K | Material definitive agreement | −1.1% (−2.0% vs SPY) | −1.1% (−2.4% vs SPY) | +4.9% (+3.2% vs SPY) |
| Jun 16, 2026 | 8-K | Material definitive agreement | +1.8% (+2.4% vs SPY) | −1.3% (+1.3% vs SPY) | +8.1% (+8.4% vs SPY) |
| May 13, 2026 | 8-K | Material definitive agreement | −12.1% (−12.8% vs SPY) | −9.3% (−9.2% vs SPY) | −8.0% (−8.0% vs SPY) |
| May 13, 2026 | Earnings | Earnings: missed the EPS estimate by -11.5% | +2.7% (+2.2% vs SPY) | −8.2% (−7.6% vs SPY) | −5.8% (−5.8% vs SPY) |
| May 5, 2026 | Insider sale | Zerillo Jeffrey sold $66K | +0.8% (0.0% vs SPY) | −8.8% (−11.7% vs SPY) | −19.7% (−24.6% vs SPY) |
| Mar 20, 2026 | 8-K | Material definitive agreement | +1.5% (+3.0% vs SPY) | +0.5% (+2.5% vs SPY) | −2.3% (−9.8% vs SPY) |
| Feb 11, 2026 | Insider sale | Zerillo Jeffrey sold $66K | −0.2% (−0.2% vs SPY) | +0.6% (+1.5% vs SPY) | −6.6% (−2.7% vs SPY) |
| Feb 5, 2026 | Earnings | Earnings: missed the EPS estimate by -1.4% | −2.2% (−1.0% vs SPY) | −1.6% (−2.4% vs SPY) | +0.2% (+2.3% vs SPY) |
| Nov 25, 2025 | Insider sale | Byom John E sold $178K | +2.6% (+1.7% vs SPY) | +3.8% (+1.9% vs SPY) | +8.3% (+4.8% vs SPY) |
| Nov 6, 2025 | Earnings | Earnings: missed the EPS estimate by -11.3% | +2.5% (+3.6% vs SPY) | +1.1% (+0.3% vs SPY) | +1.6% (+0.5% vs SPY) |
Insiders’ record here
In the year on the chart, Prestige Consumer Healthcare's insiders reported 0 open-market buys ($0) and 3 sales ($310K). Of the 3 old enough to score, 2 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale −11.3%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 2.01 Completed acquisition or disposition | 2,671 | +0.1% | 52% | +1.2% | ±1.6% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Prestige Consumer Healthcare: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.